Skip to main content
OpenTrials

Clinical trial condition

Urinary Bladder Diseases

Explore clinical trials studying Urinary Bladder Diseases. Study availability and eligibility vary by location and protocol.

2,289 public trials 413 recruiting studies
Refine in advanced search Browse all conditions

Urinary Bladder Diseases trial results

Active, Not Recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, +9 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Los Angeles, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site New Haven, Connecticut, United States
View all 188 locations
View Trial Details
Active, Not Recruiting

Intravesical BCG vs GEMDOCE in NMIBC

NCT05538663

Conditions
Carcinoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +13 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 229 locations
View Trial Details
Active, Not Recruiting

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

NCT03504163

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (All protocol activities) Commack, New York, United States
View Trial Details
Active, Not Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

NCT05843448

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, +12 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View Trial Details
Active, Not Recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 0043) Phoenix, Arizona, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0035) Fullerton, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005) Los Angeles, California, United States
  • University of California San Francisco ( Site 0010) San Francisco, California, United States
View all 188 locations
View Trial Details
Active, Not Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

NCT03317158

Conditions
Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +15 more
Locations
  • BCG Oncology Phoenix, Arizona, United States
  • Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
View Trial Details

Related conditions